Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats

A. Dhavaleshwar, Bharti Chogtu, Deepak Nayak, Praveen Kumar S. E.
{"title":"Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats","authors":"A. Dhavaleshwar, Bharti Chogtu, Deepak Nayak, Praveen Kumar S. E.","doi":"10.18203/2319-2003.ijbcp20214886","DOIUrl":null,"url":null,"abstract":"Background: The clinical studies have shown contrary results regarding hepatoprotective effect of statins. However, antifibrotic properties of statins in in vitro and in vivo experimental models have been demonstrated. The purpose of this study was to assess and compare the effect of statins on serum liver enzymes and their antifibrotic effects.Methods: Forty two rats were divided into 7 groups (I to VII) (n=6). Liver toxicity was induced by injecting carbon tetrachloride (1 ml/kg). Control groups received corn oil (0.1 ml/100 gm) and carboxy methyl cellulose (0.50%) respectively. Group III to VII received carbon tetrachloride (CCl4) for 6 weeks and then groups IV, V, VI and VII received simvastatin (10 mg/kg), atorvastatin (15 mg/kg), rosuvastatin (2 mg/kg) and silymarin (50 mg/kg) for another 8 weeks respectively. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels were estimated in all the groups at baseline, 6 weeks and 14 weeks. At 14 weeks, histopathology of liver was done in all groups.Results: At 14 weeks, all the test groups (IV, V and VI) showed a significant decrease in serum ALT, AST and ALP levels as compared to control (p<0.05) and group III (p<0.05). On intergroup comparison, liver enzymes in rats in group VI (rosuvastatin) and group V (atorvastatin) were decreased more in comparison to group IV (simvastatin) but the difference was not statistically significant except for AST levels where the difference was significant between the statins. There was decrease in hepatic fibrosis by statins with rosuvastatin being superior followed by atorvastatin and simvastatin.Conclusions: In the present study statins decreased the serum AST, ALT and ALP levels and histopathological changes were reversed by statins in CCl4 induced hepatotoxic models.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"121 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Basic & Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.ijbcp20214886","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The clinical studies have shown contrary results regarding hepatoprotective effect of statins. However, antifibrotic properties of statins in in vitro and in vivo experimental models have been demonstrated. The purpose of this study was to assess and compare the effect of statins on serum liver enzymes and their antifibrotic effects.Methods: Forty two rats were divided into 7 groups (I to VII) (n=6). Liver toxicity was induced by injecting carbon tetrachloride (1 ml/kg). Control groups received corn oil (0.1 ml/100 gm) and carboxy methyl cellulose (0.50%) respectively. Group III to VII received carbon tetrachloride (CCl4) for 6 weeks and then groups IV, V, VI and VII received simvastatin (10 mg/kg), atorvastatin (15 mg/kg), rosuvastatin (2 mg/kg) and silymarin (50 mg/kg) for another 8 weeks respectively. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels were estimated in all the groups at baseline, 6 weeks and 14 weeks. At 14 weeks, histopathology of liver was done in all groups.Results: At 14 weeks, all the test groups (IV, V and VI) showed a significant decrease in serum ALT, AST and ALP levels as compared to control (p<0.05) and group III (p<0.05). On intergroup comparison, liver enzymes in rats in group VI (rosuvastatin) and group V (atorvastatin) were decreased more in comparison to group IV (simvastatin) but the difference was not statistically significant except for AST levels where the difference was significant between the statins. There was decrease in hepatic fibrosis by statins with rosuvastatin being superior followed by atorvastatin and simvastatin.Conclusions: In the present study statins decreased the serum AST, ALT and ALP levels and histopathological changes were reversed by statins in CCl4 induced hepatotoxic models.
比较他汀类药物对四氯化碳致Wistar大鼠肝纤维化的影响
背景:他汀类药物的肝保护作用与临床研究结果相反。然而,他汀类药物的抗纤维化特性已经在体外和体内实验模型中得到证实。本研究的目的是评估和比较他汀类药物对血清肝酶的影响及其抗纤维化作用。方法:42只大鼠分为7组(I ~ VII) (n=6)。注射四氯化碳(1 ml/kg)致肝毒性。对照组分别给予玉米油(0.1 ml/100 gm)和羧甲基纤维素(0.50%)。III至VII组给予四氯化碳(CCl4)治疗6周,IV、V、VI和VII组分别给予辛伐他汀(10 mg/kg)、阿托伐他汀(15 mg/kg)、瑞舒伐他汀(2 mg/kg)和水飞蓟素(50 mg/kg)治疗8周。在基线、6周和14周时测定各组血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和碱性磷酸酶(ALP)水平。14周时,各组进行肝脏组织病理学检查。结果:14周时,各试验组(IV、V、VI)血清ALT、AST、ALP水平均显著低于对照组(p<0.05)和III组(p<0.05)。在组间比较中,与IV组(辛伐他汀)相比,VI组(瑞舒伐他汀)和V组(阿托伐他汀)大鼠肝酶下降更多,但差异无统计学意义,但AST水平在他汀类药物之间差异有统计学意义。他汀类药物减少肝纤维化,瑞舒伐他汀效果最好,其次是阿托伐他汀和辛伐他汀。结论:在本研究中,他汀类药物可降低CCl4肝毒性模型血清AST、ALT和ALP水平,并可逆转组织病理变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信